Bibliographic Info
GuidelineConsolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations
Year of Publication2022
Issuing InstitutionWHO
Recommendation
Status
Maintained
Recommended in favor
Strong
Certainty of evidence
High
Oral pre-exposure prophylaxis (PrEP) containing tenofovir disoproxil fumarate (TDF) should be offered as an additional prevention choice for people at substantial risk of HIV infection as part of combination HIV prevention approaches
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach
Year2016
InstitutionWHO
Guideline
Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach
Year2021
InstitutionWHO
Guideline
WHO recommendations on maternal and newborn care for a positive postnatal experience.
Year2022
InstitutionWorld Health Organization